-
Biosimilar Bevacizumab Matches Avastin in Treating Retinopathy of Prematurity
15 Oct 2025 21:28 GMT
… since the BEAT-ROP trial established its ability to … large-scale randomized controlled trials. The authors emphasized the … for biosimilars to broaden treatment access and reduce healthcare … Stivant) versus reference product (Avastin) in prethreshold type I …
-
<![CDATA[Real-World Data Shows Vision Decline as Copay Programs Run Dry | AAO 2025]]>
18 Oct 2025 00:20 GMT
… doses, 39% extended treatment intervals, and 26% stopped treatment entirely. As a … macular edema (DME). Avastin (bevacizumab) is an oncology drug that is used … among those covered through Medicare Advantage plans. “Medicare Advantage patients account for …
-
<![CDATA[Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC]]>
16 Oct 2025 19:08 GMT
… or without bevacizumab (Avastin) exhibited an overall … trial (NCT05116189), according to a news release from the drug … Medical Oncology (ESMO) Congress 2025.
“The results from the KEYNOTE-B96 trial … with limited options for treatment, and this impactful …
-
<![CDATA[Poll Results Reveal Readers’ Top GI Cancer Abstracts for ESMO 2025]]>
15 Oct 2025 18:02 GMT
… 2025 European Society of Medical Oncology (ESMO) Congress … atezolizumab/bevacizumab (Avastin) regimen in first-line … the the phase 3 trial CASSANDRA trial (NCT04793932) is … regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: …
-
<![CDATA[ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors]]>
13 Oct 2025 22:18 GMT
… trial may “lead to a third TOPO1 antibody drug … overcome the limitations of bevacizumab [Avastin] in treating squamous [NSCLC … treatment for patients with HER2-mutated NSCLC.
In May 2025, the FDA … deputy medical director of the Phase 1 Clinical Trials Centre …
-
Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Date of authorisation: 15/01/2018, Revision: 15, Status: Authorised
12 Feb 2018 11:09 GMT
… a prescription and treatment should be supervised by a doctor who has … and the other cancer medicines being used. The treatment is continued until … to those of the reference medicine Avastin.
The most common side effects …
-
Merck's Keytruda follows primary endpoint win in ovarian cancer study with OS triumph
17 Oct 2025 01:05 GMT
… up dozens of FDA-approved indications, the drug is showing it … , again with or without Avastin.
Previously, Merck hailed a … prognosis with limited options for treatment, and this impactful news … share detailed results at medical meetings and with regulators …
-
<![CDATA[Biosimilar Stivant Shows Noninferior Efficacy and Comparable Safety to Reference Bevacizumab]]>
16 Oct 2025 20:43 GMT
… nonrandomized, contralateral clinical trial, preterm infants with … therapeutic response to treatment with Stivant and Avastin. Alternatively, … drug-related AEs in the eyes receiving Stivant or Avastin … , larger randomized controlled trials,” wrote the study …
-
<![CDATA[Pembrolizumab Plus Chemo With or Without Bevacizumab Improves OS in Platinum-Resistant Ovarian Cancer]]>
16 Oct 2025 19:50 GMT
… with or without bevacizumab (Avastin) led to a statistically … prognosis with limited options for treatment, and this impactful news … -based regimen.3 Prior treatment with a PARP inhibitor, … medical meeting.
References
Merck announces phase 3 KEYNOTE-B96 trial …
-
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
16 Oct 2025 14:47 GMT
… AG’s (OTC:RHHBY) Avastin (bevacizumab).
The trial met its secondary endpoint … New HIV Treatment Works As Well As Top Drug In Late Trials
In … the upcoming European Society for Medical Oncology (ESMO) Congress 2025.
The …
About
© 1995-2025